Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC

Fig. 7

DOC enhanced the recruitment of HER2-CAR T cells to tumor microenvironment in vivo. a Treatment scheme showing the timing of mice experiments. b, c Immunohistochemistry results showed that the expression of HER2-CAR T in untreated, DOC treated, HER2-CAR T cell treated, or DOC in combination with HER2-CAR T treated groups. Scale bars, 20 μm. d FSC results showed that the expression of HER2-CAR T in CAR-T cell treated, or DOC in combination with CAR-T cell treated groups. Data are given as means ± SEM. **P < 0.0001. e QRT-PCR results showed the expression of HMGB1 and CXCL11 in untreated, DOC treated, HER2-CAR T cell treated, or DOC in combination with HER2-CAR T cell treated groups. An overall difference between the groups was determined by one-way ANOVA. *P < 0.05; **P < 0.0001. f Tumor growth was measured in untreated, DOC, CAR-T cell, and DOC in combination with CAR-T cell treated groups. Significant differences between each group are indicated by *, P < 0.05; **P < 0.0001

Back to article page